Business Context and Reporting Period
Company: TOMI Environmental Solutions, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2011
Business Overview: TOMI operates as a global decontamination and infectious disease control company. Its primary products include Hydrogen Peroxide aerosols, Ultra-Violet Ozone Generators, and Ultra-Violet Germicidal Irradiation (UVGI) technologies designed for indoor surface decontamination in medical facilities, commercial structures, and residential units. The company shifted its strategy in 2011 from direct service provision to licensing and selling equipment to third parties.
Key Financial Metrics
| Metric | 2011 | 2010 |
|---|---|---|
| Net Revenue | $208,399 | $357,167 |
| Gross Profit | $71,240 | $211,871 |
| Gross Margin | 34.2% | 59.3% |
| Net Loss | $(826,510) | $(1,538,923) |
| Loss Per Share (Basic/Diluted) | $(0.01) | $(0.04) |
| Cash and Cash Equivalents (End of Period) | $0 | $61,179 |
| Net Cash Used in Operating Activities | $(329,323) | $(278,080) |
| Total Assets | $125,881 | $314,754 |
| Total Liabilities | $397,063 | $1,323,076 |
| Stockholders' Equity (Deficiency) | $(271,182) | $(1,008,322) |
| Working Capital | $(379,942) | $(1,256,878) |
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 42% from $357,167 in 2010 to $208,399 in 2011. Management attributes this to a strategic shift away from direct service provision toward licensing and equipment sales.
- Improved Net Loss: The net loss narrowed significantly from $1.54 million in 2010 to $826,510 in 2011. This improvement was driven by a reduction in general and administrative expenses and the absence of a $902,500 acquisition-related expense recorded in 2010 (which was reversed in 2010).
- Liquidity Crisis: Cash and cash equivalents dropped to zero by year-end 2011, down from $61,179 in 2010. The company reported a cash overdraft of $1,309.
- Debt Structure: The company issued a $75,000 convertible promissory note in November 2011. Total liabilities decreased due to the forgiveness of $700,269 in accrued officer compensation by the CEO, which was recorded as a capital contribution.
Outlook, Risks, and Management Commentary
- Going Concern Warning: The independent auditors issued a "going concern" opinion. The company has a working capital deficiency and has not generated positive cash flow from operations. Continued existence is dependent on raising additional capital through equity or debt financing.
- Capital Needs: Management states an "immediate and urgent need for additional capital." Plans include issuing restricted stock, convertible notes, and pursuing licensing arrangements.
- Operational Risks:
- Competition: The industry is highly competitive with larger rivals (e.g., BioQuell, Johnson & Johnson) possessing greater resources.
- Distribution Rights: The company's right to distribute hydrogen peroxide aerosol is contingent on meeting sales milestones; failure to do so could terminate the agreement.
- Key Personnel: The company relies heavily on its CEO, Dr. Halden S. Shane, who owns approximately 21.4% of the outstanding common stock.
- Subsequent Events: Following the reporting period, the company sold a $100,000 convertible note in February 2012 and issued additional common stock for legal fees and private placements.
Investor Verification Checklist
- Cash Position: Verify the current cash balance, as the company reported $0 cash at year-end 2011.
- Capital Raising: Confirm if the company has successfully secured the additional financing required to maintain operations as stated in the "Going Concern" note.
- Revenue Strategy: Assess the progress of the shift to a licensing model and the status of the first hydrogen peroxide aerosol unit sale to a major metropolitan hospital.
- Convertible Debt: Review the terms of the $75,000 (2011) and $100,000 (2012) convertible notes, specifically the "ratchet" provisions that allow conversion prices to adjust downward, which may cause significant dilution.
- Related Party Transactions: Monitor the status of accrued officer compensation and the CEO's forgiveness of debt, which significantly impacted the balance sheet.